Artificial intelligence systems are beginning to function as “co-scientists” in cancer research, generating drug candidates, prioritizing immunotherapy targets, and guiding experimental design.

1Integrative Anthropological Sciences, University of California, Santa Barbara, Santa Barbara, California. *Corresponding Author: Amy M. Boddy, Integrative ...

1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.

Abstract. At its core, cancer is a disease of uncontrolled cell proliferation mediated by perturbed molecular pathways that have been elucidated over the past few decades. Biochemical and genetic ...

Cancer Discov (2025) 15 (12): 2422–2430.

1The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2The Lung Cancer Precision Medicine Center of Excellence, Johns Hopkins University ...

PARP inhibitor sensitivity is associated with cGAS–STING–IFN signaling, which can be harnessed by combining PARP inhibitors with STING agonists to overcome acquired resistance and requires NK cells to ...

1Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.

Abstract. Molecular glue degrader (MGD) is an emerging therapeutic strategy offering an exciting alternative to traditional small molecules exploring new target space. These small molecules interact ...

The combination of anti-TROP2 ADCs with PD-(L)1 inhibitors represents a promising therapeutic strategy, merging targeted therapy with immunotherapy to improve treatment outcomes. Clinical trials are ...

University of Maryland, Baltimore, Baltimore, MD.

Abstract. TNG462 is a clinical-stage, MTA-cooperative PRMT5 inhibitor currently being evaluated in an ongoing phase I/II clinical trial for solid tumors with MTAP loss. Approximately 10-15% of all ...